SOD2 Human shRNA Lentiviral Particle (Locus ID 6648)
CAT#: TL309190V
SOD2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
Need custom lentivirus service?
Get a free quote
CNY 11,400.00
货期*
详询
规格
Cited in 1 publication. |
Product images
经常一起买 (3)
Specifications
Product Data | |
Product Name | SOD2 Human shRNA Lentiviral Particle (Locus ID 6648) |
Locus ID | 6648 |
Synonyms | GClnc1; IPO-B; IPOB; Mn-SOD; MNSOD; MVCD6 |
Vector | pGFP-C-shLenti |
Format | Lentiviral particles |
RefSeq | BC016934, NM_000636, NM_001024465, NM_001024466, NM_001322814, NM_001322815, NM_001322816, NM_001322817, NM_001322819, NM_001322820, NM_000636.1, NM_000636.2, NM_000636.3, NM_001024465.1, NM_001024465.2, NM_001024466.1, NM_001024466.2, BC016934.1, BC012423, BC012423.1, BC001980, BC016015, BC035422, BC041951, BM724413, BM994509, NM_000636.4, NM_001024465.3, NM_001024466.3 |
Summary | This gene is a member of the iron/manganese superoxide dismutase family. It encodes a mitochondrial protein that forms a homotetramer and binds one manganese ion per subunit. This protein binds to the superoxide byproducts of oxidative phosphorylation and converts them to hydrogen peroxide and diatomic oxygen. Mutations in this gene have been associated with idiopathic cardiomyopathy (IDC), premature aging, sporadic motor neuron disease, and cancer. Alternative splicing of this gene results in multiple transcript variants. A related pseudogene has been identified on chromosome 1. [provided by RefSeq, Apr 2016] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
,null,
International journal of molecular sciences
,PubMed ID 37175412
[SOD2]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...